S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.64 (+1.37%)
AAPL   116.45 (+0.55%)
MSFT   212.24 (+0.91%)
FB   266.83 (+1.88%)
GOOGL   1,483.41 (+1.22%)
AMZN   3,218.28 (+2.21%)
TSLA   447.55 (+4.32%)
NVDA   542.80 (+0.29%)
BABA   289.16 (-1.64%)
CGC   14.11 (-1.47%)
MU   47.62 (+1.41%)
GE   6.21 (-0.32%)
AMD   84.69 (+3.29%)
T   28.43 (-0.28%)
F   6.71 (+0.75%)
ACB   4.67 (+0.43%)
GILD   63.00 (-0.30%)
NFLX   526.18 (+5.23%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   23.99 (-0.42%)
S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.64 (+1.37%)
AAPL   116.45 (+0.55%)
MSFT   212.24 (+0.91%)
FB   266.83 (+1.88%)
GOOGL   1,483.41 (+1.22%)
AMZN   3,218.28 (+2.21%)
TSLA   447.55 (+4.32%)
NVDA   542.80 (+0.29%)
BABA   289.16 (-1.64%)
CGC   14.11 (-1.47%)
MU   47.62 (+1.41%)
GE   6.21 (-0.32%)
AMD   84.69 (+3.29%)
T   28.43 (-0.28%)
F   6.71 (+0.75%)
ACB   4.67 (+0.43%)
GILD   63.00 (-0.30%)
NFLX   526.18 (+5.23%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   23.99 (-0.42%)
S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.64 (+1.37%)
AAPL   116.45 (+0.55%)
MSFT   212.24 (+0.91%)
FB   266.83 (+1.88%)
GOOGL   1,483.41 (+1.22%)
AMZN   3,218.28 (+2.21%)
TSLA   447.55 (+4.32%)
NVDA   542.80 (+0.29%)
BABA   289.16 (-1.64%)
CGC   14.11 (-1.47%)
MU   47.62 (+1.41%)
GE   6.21 (-0.32%)
AMD   84.69 (+3.29%)
T   28.43 (-0.28%)
F   6.71 (+0.75%)
ACB   4.67 (+0.43%)
GILD   63.00 (-0.30%)
NFLX   526.18 (+5.23%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   23.99 (-0.42%)
S&P 500   3,379.24 (+0.48%)
DOW   27,806.73 (+0.09%)
QQQ   281.64 (+1.37%)
AAPL   116.45 (+0.55%)
MSFT   212.24 (+0.91%)
FB   266.83 (+1.88%)
GOOGL   1,483.41 (+1.22%)
AMZN   3,218.28 (+2.21%)
TSLA   447.55 (+4.32%)
NVDA   542.80 (+0.29%)
BABA   289.16 (-1.64%)
CGC   14.11 (-1.47%)
MU   47.62 (+1.41%)
GE   6.21 (-0.32%)
AMD   84.69 (+3.29%)
T   28.43 (-0.28%)
F   6.71 (+0.75%)
ACB   4.67 (+0.43%)
GILD   63.00 (-0.30%)
NFLX   526.18 (+5.23%)
DIS   123.28 (-0.64%)
BA   167.16 (+1.15%)
BAC   23.99 (-0.42%)
Log in
NASDAQ:SYN

Synthetic Biologics Stock Forecast, Price & News

$0.46
-0.01 (-2.19 %)
(As of 10/1/2020 02:57 PM ET)
Add
Compare
Today's Range
$0.44
Now: $0.46
$0.47
50-Day Range
$0.45
MA: $0.52
$0.64
52-Week Range
$0.25
Now: $0.46
$0.75
Volume4,828 shs
Average Volume458,814 shs
Market Capitalization$9.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYN
CUSIPN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$9.03 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$0.46
-0.01 (-2.19 %)
(As of 10/1/2020 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synthetic Biologics (NASDAQ:SYN) Frequently Asked Questions

How has Synthetic Biologics' stock been impacted by COVID-19?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SYN shares have increased by 29.0% and is now trading at $0.4643.
View which stocks have been most impacted by COVID-19
.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc (NASDAQ:SYN) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.18) earnings per share for the quarter.
View Synthetic Biologics' earnings history
.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Amarin (AMRN), Vaxart (VXRT), Crispr Therapeutics (CRSP), Occidental Petroleum (OXY), Altimmune (ALT), ImmunoGen (IMGN), Micron Technology (MU), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV) and Verastem (VSTM).

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
  • Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the NASDAQ under the ticker symbol "SYN."

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.46.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $9.03 million.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.